Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  ONO PHARMACEUTICAL CO., LTD.    4528   JP3197600004

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

ONO PHARMACEUTICAL CO., LTD. : Voluntary adoption of International Financial Reporting Standards (IFRS)(64.9KB)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/13/2013 | 01:15pm CET

May 13, 2013
ONO PHARMACEUTICAL CO., LTD. Corporate Communications
TEL: +81-6-6263-5670

Voluntary adoption of International Financial Reporting Standards (IFRS)

Ono Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, President: Gyo Sagara) resolved at the meeting of Board of Directors held today that IFRS is to be adopted to its group's consolidated financial reports and consolidated calculation documents ending on March 31st, 2014. Its financial reports and documents used to be based on Japan Generally Accepted Accounting Principles (Japan GAAP).
Our group has been facilitating business development such as research and development and licensing activities globally in the U.S.A, Europe and Asian regions as well as in Japan. Additionally foreign investors account for about 30 % of the total shareholders as of March 31st,
2013, which has shown large proportion of foreign investors from the past. With these situations considered, we have decided to voluntarily adopt IFRS to disclose financial information based on international standards, improve comparability and enhance convenience of stakeholders
including shareholders, investors and business partners.
Ref: <Schedule of disclosure of financial information in association with the change of accounting standards>

May 2013

Flash Report and consolidated calculation document ending on

March 31st, 2013

Japan GAAP

June 2013

Annual Report ending on March 31st, 2013

Japan GAAP

Financial information on 1Q to 3Q ending on March 31st, 2014

Japan GAAP

May 2014

Flash Report and consolidated calculation document ending on

March 31st, 2014

IFRS

June 2014

Annual Report ending on March 31st, 2014

IFRS

Consolidated Financial Forecast in Fiscal Year ended March 31, 2014 (FY2013) under IFRS

Table below shows trial IFRS calculation of the consolidated forecast for the fiscal year ending March 31, 2014, disclosed today.

(Billion JPY)

IFRS (1)

J-GAAP (2)

Difference ((1) - (2))

Net sales

146.3

148.3

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ONO PHARMACEUTICAL CO., LT
02/15 LAUNCH OF PARSABIV® INTRAVENOUS INJE : Etelcalcetide Hydrochloride), a Calcimime..
02/08 ONO PHARMACEUTICAL : U.S. Food and Drug Administration Approves Parsabiv™ ..
02/06 ONO PHARMACEUTICAL : Certain Media Coverage Related to ONO Reported on February ..
02/03 ONO PHARMACEUTICAL : Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivo..
02/02 Bristol-Myers Squibb and Ono Pharmaceutical Company Enter Settlement and Lice..
01/24 BRISTOL-MYERS SQUIBB CO (NYSE : BMY) To Share In Sales Of Merck & Co., Inc. (NYS..
01/21 ONO PHARMACEUTICAL : and Bristol-Myers Squibb Enter Settlement and License Agree..
01/20 ONO PHARMACEUTICAL : Bristol-Myers Squibb Provides Regulatory Update in First-li..
01/20 ONO PHARMACEUTICAL : Data with OPDIVO® (nivolumab) Intravenous Infusion in Gastr..
2016 ONO PHARMACEUTICAL : Submits Supplemental Application of OPDIVO® (Nivolumab) for..
More news
Sector news : Generic Pharmaceuticals
02/17DJSHIRE : Files 8K - Other Events
02/17 European shares retreat after week of gains; Allianz rallies after update
02/17 ASTRAZENECA : Top AstraZeneca shareholder Woodford adds to stake, bullish on out..
02/17DJROCHE : U.S. Obtains Records in Lobbyist Probe -- WSJ
02/17DJASTRAZENECA : Trial For Breast Cancer Treatment Shows Positive Results
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
01/23 Bristol Catches A Break At Last
2016 Opdivo's price halved in Japan
2016 Bristol's Bid To Get Ahead In Head And Neck
2016 A European Biotech Stock Basket For 2016 - Update
Advertisement
Financials ( JPY)
Sales 2017 250 398 M
EBIT 2017 -
Net income 2017 53 292 M
Finance 2017 124 853 M
Yield 2017 1,67%
P/E ratio 2017 25,13
P/E ratio 2018 27,01
EV / Sales 2017 5,42x
EV / Sales 2018 5,21x
Capitalization 1 482 227 M
More Financials
Chart ONO PHARMACEUTICAL CO., LT
Duration : Period :
ONO PHARMACEUTICAL CO., LT Technical Analysis Chart | 4528 | JP3197600004 | 4-Traders
Full-screen chart
Technical analysis trends ONO PHARMACEUTICA...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 3 053  JPY
Spread / Average Target 21%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gyo Sagara President & Representative Director
Shozo Matsuoka Executive Officer & Manager-Medical Affairs
Kazuhito Kawabata Director & Managing Executive Officer
Hiroshi Awata Director, EVP & General Manager-Development
Isao Ono Director & Managing Executive Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ONO PHARMACEUTICAL CO...-1.68%13 131
OTSUKA HOLDINGS CO LTD2.26%25 737
SUN PHARMACEUTICAL IND..7.05%24 168
ASPEN PHARMACARE HOLDI..1.60%10 094
SHANGHAI FOSUN PHARMAC..8.17%8 745
TAISHO PHARMACEUTICAL ..-3.91%7 450
More Results